Introduction {#sec1_1}
============

Diarrheal disease is a major health problem, with approximately 1.7 billion cases reported globally each year \[[@B1]\]. It is also a leading cause of malnutrition and the second leading cause of death in children under 5 years of age, killing approximately 760,000 of them each year \[[@B1]\]. The economic cost of treatment of diarrhea is also considerable \[[@B2]\]. Diarrheal disease is caused by a variety of pathogens including bacteria, parasites and viruses. Accurate identification of diarrheal agents is necessary for provision of appropriate therapy and containment of outbreaks. However, conventional microbiology for the diagnosis of diarrhea is time-consuming, requires up to 2-3 days to get all the results (even though microscopy for ova and parasites is fast, bacterial culture is delayed), labor- intensive involving multiple techniques (microscopy, culture, immunological assay) and hampered by low sensitivity \[[@B3]\]. On the other hand, molecular biological techniques based on the detection of specific nucleic acid sequences are rapid and more sensitive \[[@B2]\]. Many molecular tests have been published for enteric pathogens \[[@B4],[@B5]\]; however, they mostly detected few pathogens, were developed in-house and have not undergone extensive evaluation \[[@B4],[@B5]\]. Hence, multiplex tests that detect several pathogens in a single assay are desirable. One such test is the xTAG \[gastrointestinal pathogen panel (GPP) assay, a multiplexed molecular test marketed by Luminex Corporation (Austin, Tex., USA)\]. This assay detects up to 15 different pathogens responsible for \>90s% of infectious diarrhea from human stool samples with a turnaround time of about 5 h \[[@B6]\]. The pathogens detected are: bacteria *(Salmonella* spp., *Shigella* spp., *Vibrio cholerae, Yersinia enterocolitica, Campylobacter* spp., *Clostridium difficile, Escherichia coli* O157, Shiga toxin-producing *E. coli* and enterotoxigenic *E. coli),* viruses (rotavirus A, adenovirus 40/41 and norovirus GI/GII) and parasites *(Cryptosporidium* spp., *Entamoeba histolytica* and *Giardia lamblia).* Hence, the primary objective of the study was to evaluate the utility of this assay in Kuwait. Furthermore, since the last comprehensive study on the etiology of diarrhea in Kuwaiti in the 1980s \[[@B7]\], many diarrheal pathogens have been discovered \[[@B8]\]. Hence, a secondary objective of the study was to evaluate the relative distribution of various etiological agents detected by the xTAG GPP assay in diarrheal stool samples.

Materials and Methods {#sec1_2}
=====================

Collection of Diarrheal Stool Samples {#sec2_1}
-------------------------------------

Consecutive diarrheal stool samples from patients hospitalized at Mubarak Al-Kabeer Hospital, Kuwait (one sample per patient of any age group) received at the Clinical Microbiology Laboratory of Mubarak Al-Kabeer Hospital from March 2014 to June 2015 were used for evaluation. Specimens were collected \<48 h after hospitalization of patients.

### Luminex xTAG GPP Assay {#sec3_1}

This assay was performed on thawed stool samples frozen at −70°C as per the manufacturer\'s instructions. Nucleic acid was extracted from pretreated stool samples by the NucliSENS Easy MAG system (bioMerieux, Marcy l\'Etoile, France). The xTAG GPP assay included an RNA-based internal control (MS2 bacteriophage) to monitor the entire assay performance. The other steps involved reverse transcription polymerase chain reaction (RT-PCR) and subsequent hybridization. The PCR amplification was performed using a GeneAmp PCR system 9700 thermal cycler (Applied Biosystems, Forster City, Calif., USA) with the recommended cycling parameters. The data were acquired with the Luminex MagPix analyzer, and data analysis was carried out using TDAS data analysis software. The results obtained using conventional assays were not revealed until the xTAG GPP assay was completed.

### Conventional Assays {#sec3_2}

*Bacteria.* Detection of *Salmonella* spp., *Shigella* spp. and *V. cholerae* was done by methods described previously \[[@B9]\], with a minor modification. Instead of taurocholate-tellurite-gelatin agar, thiosulfate-citrate-bile salt-sucrose (TCBS) agar was used for culturing vibrios. Briefly, fresh stool specimens were cultured on MacConkey agar (Oxoid, Basingstoke, UK), *Salmonella-Shigella* (SS) agar (Oxoid), TCBS agar (Eiken, Tokyo, Japan), CampyBAP agar (Becton-Dickinson, Franklin Lakes, N.J., USA) and in Selenite F broth (Oxoid). All media except CampyBAP were incubated in an ambient atmosphere at 37°C for 24 h. Selenite F broth was subcultured onto SS agar, after which the agar medium was incubated for 24 h as described above. CampyBAP agar was incubated at 42°C for 48 h in a microaerobic atmosphere. Characteristic, lactose-nonfermenting pale colonies on the MacConkey agar and SS agar were screened for *Salmonella* spp. and *Shigella* spp. by Kligler\'s iron agar (Oxoid) and subsequently by API-20 E biochemical strip (bioMerieux). Sucrose-fermenting yellow colonies on TCBS agar were screened for vibrios by biochemical reactions as described above. If biochemical reactions were suggestive, *Salmonella* spp., *Shigella* spp. and *V. cholerae* O1 and O139 were confirmed by slide agglutination test with specific antisera (Denka-Seiken, Tokyo, Japan). Suspected *Campylobacter* spp. colonies on CampyBAP were confirmed by characteristic morphology on Gram stain and motility as well as by positive oxidase and catalase tests. Entire nonmucoid lactose-fermenting colonies resembling *E. coli* from the MacConkey agar were stored in Luria broth with 30s% glycerol at −70°C until tested for selected categories of diarrheagenic *E. coli* \[[@B10]\]. *C. difficile* was detected directly in stool samples by the Xpert® *C. difficile* (Cephid, Sunnyvale, Calif., USA) assay which detects genes encoding cytotoxin B and binary toxin. Since *Y. enterocolitica* infection is extremely rare in Kuwait, this pathogen was not searched for.

*Parasites. G. lamblia* and *E. histolytica* were detected by light microscopy of wet amount after formalin-ethyl acetate sedimentation concentration of parasites in the stool using the FPC Fecal Parasite Concentrator kit (Evergreen, Vernon, Calif., USA). *Cryptosporidium* spp. was detected by cold acid-fast staining of stool smear \[[@B11]\].

*Viruses.* Group A rotavirus was detected by enzyme-linked immunosorbent assay using the Premier rotaclone kit (Meridian Bioscience, Cincinnati, Ohio, USA). Noroviruses (groups I and II) were detected by RT-PCR \[[@B12]\], and enteric adenoviruses 40/41 (group F) by PCR \[[@B13]\].

Statistics {#sec2_2}
----------

The sensitivity of the xTAG GPP assay was calculated by comparison of pathogen yield with that of conventional assays. For example, if the pathogen yield of conventional assays is 1n and that of the xTAG GPP assay is 2n, with the sensitivity of the conventional assays being 100s%, the sensitivity of the xTAG GPP assay is 2n × 100/1n = 200s%.

Results {#sec1_3}
=======

The pathogens detected are shown in table [1](#T1){ref-type="table"}. From the 109 stool samples, 20 (18.4s%) pathogens were detected by the xTAG GPP assay, compared to 10 (9.2s%) pathogens using conventional methods from 19 patients. Among these 19 patients, 9 (8.3s%) had identical pathogens (a total of 10) detected by both methods. These pathogens included *Salmonella* spp., *C. difficile*, rotavirus and norovirus in 2 patients each and a *Salmonella* sp. and *C. difficile* in 1 patient. In addition, 10 (9.2s%) patients were positive for single pathogens using the xTAG GPP assay only. These pathogens included: *Shigella* sp. (1 patient), *Campylobacter* spp. (6 patients), *Cryptosporidium* sp. (1 patient) and *G. lamblia* (2 patients). The pathogens not detected by conventional assays were *Shigella* sp., *Campylobacter* spp., *Cryptosporidium* spp. and *G*. *lamblia.*

Using conventional assays which are considered to be the gold standard, 10 pathogens were detected, while twice as many pathogens (20 pathogens) were detected using the xTAG GPP assay, showing its superiority.

Discussion {#sec1_4}
==========

In this study, both the xTAG GPP assay and the conventional methods detected 3 *Salmonella* spp., 3 *C. difficile*, 2 rotavirus and 3 norovirus out of 109 diarrheal stool samples. The xTAG GPP assay detected additional pathogens that were missed by the conventional methods. These pathogens included 1 *Shigella* sp., 6 *Campylobacter* spp., 1 *Cryptosporidium* sp. and 2 *G. lamblia.* Thus, the sensitivity of the xTAG GPP assay in our study was 200s%.

Several independent studies have evaluated the performance of the xTAG GPP assay. In these studies, the sensitivity by diagnostic accuracy test varied from 92 to 100s% \[[@B14],[@B15],[@B16],[@B17],[@B18]\]. However, since the additional positives detected by the xTAG GPP assay were proven to be true positives by alternative tests, in fact, the true sensitivity of the xTAG GPP assay (as defined in our study) in these evaluations exceeded 100s%.

In this study, 9.2s% enteric pathogens detected in diarrheal stool samples by conventional methods was similar to 10s% of enteric pathogens detected in diarrheal stool sampes by conventional methods in routine diagnostic laboratories \[[@B19],[@B20],[@B21]\]. In our study, the use of the xTAG GPP assay has improved the yield of pathogens by 2-fold, detecting an additional 10 pathogens, which is similar to the results of other studies \[[@B14],[@B18],[@B22],[@B23],[@B24]\]. Conventional methods are known to be less sensitive than molecular methods for the detection of pathogens \[[@B2]\]. Our study also revealed a wide spectrum of pathogens in diarrheal cases in Kuwait. Additional pathogens detected in this study compared to the previous study in Kuwait were *C. difficile*, norovirus and *Cryptosporidium* sp. \[[@B7]\].

The xTAG GPP assay was also found to report pathogens for which tests were not requested by physicians \[[@B25],[@B26]\]. Conventional assays missed etiological agents in some diarrheal cases, and these cases were judged as diarrheas of unknown etiologies. However, the xTAG GPP assay did detect pathogens in these cases, which were *Salmonella* spp., *Campylobacter* spp. and *Cryptosporidium* spp. \[[@B22]\]. The identification of coinfections is necessary as it can help guide the most appropriate pathogen-specific therapy. In our study, only 1 patient had a coinfection - *C. difficile* with a *Salmonella* sp. However, both conventional and xTAG GPP assays detected these pathogens. The xTAG GPP assay has dramatically improved the diagnosis of coinfections as compared to conventional tests. The detection of coinfections varied from 7 to 38s% in stool specimens by the xTAG GPP assay, whereas by conventional methods, it was either zero or negligible \[[@B14],[@B22],[@B23],[@B26]\]. Although *C. difficile* was found to have the highest involvement in coinfections, it is not clear whether it represents infection or colonization \[[@B14]\]. Our testing was carried out on inpatients of all age groups. The clinical utility of the xTAG GPP assay has been proven in a variety of patient groups and settings. These include adult and pediatric patients \[[@B16],[@B22]\], immunocompromised and transplant patients \[[@B22],[@B26]\], outpatients \[[@B16]\], travelers \[[@B16],[@B22]\], outbreak situations \[[@B27],[@B28]\] as well as epidemiology and monitoring situations \[[@B23],[@B28]\]. Testing in pediatric patients with diarrhea revealed the usual array of pathogens expected in this age group, with rotavirus predominating \[[@B16]\]. Application of this test in travelers with diarrhea showed the major pathogens to be *Shigella* spp., enterotoxigenic *E. coli*, enteroaggregative *E. coli* and *G. lamblia.* Regional variation in the prevalence of enterotoxigenic *E. coli* was found \[[@B23]\]. The test also detected pathogens not found by conventional methods or not requested for testing. Thus, the test allowed a better assessment of the etiology of travelers\' diarrhea \[[@B23]\]. In transplant patients, diarrhea used to be attributed to adverse effects of immunosuppressive therapy. However, using the xTAG GPP assay, diarrheal pathogens were detected in most kidney transplant patients studied, with norovirus as the leading cause \[[@B26]\]. xTAG GPP was used to detect outbreak pathogens in the German outbreak of bloody diarrhea and hemolytic uremic syndrome due to the novel enterohemorrhagic *E. coli* O104:H4 positive for Stx 1 \[[@B27]\], as well as in the cholera epidemic in Haiti \[[@B28]\]. In both these outbreaks, the causative agents were correctly identified. With xTAG GPP, there is a shorter hands-on time, high throughput detection of multiple enteric pathogens, improved turnaround time, consolidated laboratory workflow and simplified stool culture practices which reduce the overall cost of laboratory investigation \[[@B17]\]. With a 5-hour turnaround time, it has the potential to optimize patient management and infection control practices and reduce overall hospital costs \[[@B14],[@B24]\]. However, there are some disadvantages of the xTAG GPP assay: (1) since the luminex platform uses an open system, samples are prone to amplicon contamination unless good laboratory practices are followed, and (2) conventional bacterial culture and parasitological examination are still required to detect other pathogens and to determine antimicrobial susceptibility in specific cases.

Thus, the xTAG GPP assay is a rapid test with a superior sensitivity, capable of detecting up to 15 diarrheal pathogens, as well as cost-effective, considering that all 15 pathogens are detected in a single test. However, a laboratory can also select/deselect which pathogens are detected on a patient basis. The xTAG GPP in vitro diagnostic assay kit was the first multiplex molecular test cleared by the Food and Drug Administration of the United States of America for a diagnosis of diarrheal disease after extensive evaluation \[[@B29]\]. This also gives confidence for the introduction of the assay into the routine clinical laboratory work. One limitation of our study was that the sample size was relatively small.

Conclusion {#sec1_5}
==========

In this study, the xTAG GPP assay detected all the pathogens also found by conventional methods as well as additional pathogens not detected using conventional methods. This assay is a multiplex molecular test for the simultaneous detection of up to 15 major diarrheal pathogens for a rapid and better diagnosis that might lead to appropriate treatment of diarrheal disease. Our results and those of other studies suggest that this assay can be used in different settings and countries.
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###### 

Pathogens identified by the Luminex xTAG GPP assay and conventional assays from 109 diarrheal stool samples

  Pathogen                Number of positive samples by   
  ----------------------- ------------------------------- ----
  *Salmonella* spp.       3                               3
  *Shigella* sp.          1                               0
  *Campylobacter* spp.    6                               0
  *C. difficile*          3                               3
  Rotavirus               2                               2
  Norovirus               2                               2
  *Cryptosporidium* sp.   1                               0
  *G. lamblia*            2                               0
                                                          
  Total                   20                              10
